金沙(8888js-官方JS认证)-Made in China

Be the most trusted biotech company

2024-03-21

Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved
2024-03-20

Henlius’ Trastuzumab Approved in Brazil, a Semi-Exclusive License Area, in Latin America
2024-03-15

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ ADC Candidate HLX42
2024-03-13

Henlius Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Serplulimab in ES-SCLC
2024-03-12

The IND Application of Henlius’ Novel Anti-GARP/TGF-β1 mAb HLX6018 Approved by NMPA
2024-03-07

Henlius to Present Exploratory Biomarker Analysis Results of the Pivotal Clinical Trial ASTRUM-005 of Serplulimab at AACR 2024
2024-03-05

Henlius’ Trastuzumab Plots Southeast Asia Expansion, to Enter Thailand and Philippines
2024-03-04

Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development
2024-02-29

Henlius Adalimumab Biosimilar Received sNDA Acceptance Notification from the NMPA

1
...
4
5
6
7
8
9
...
38